A Pilot Human Investigation of the Safety, Tolerability and Effectiveness of the Aqua Medical Circumferential RF Vapor (RFV) Ablation System for Duodenal Mucosal Ablation for the Management of Type-2 Diabetes Mellitus (STEAM T-2DM Pilot)

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this clinical study is to test the hypothesis that RF vapor ablation of the duodenal mucosa will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation). The main aims of the study are : 1. Evaluate the safety of the device and procedure based on the reported adverse events that occur. 2. Evaluate the effectiveness of the device and procedure by comparing change in HbA1c from baseline to 168 days post procedure. 3. Evaluate device tolerability based on pain scores reported by patients. The subject population for this study are adults (18-65 years of age) with type-2 diabetes mellitus. Study participation is 6 months for each patient. The study is comprised of 5 phases: Screening, Run-in, RF Vapor ablation procedure, and Post-vapor ablation follow-up (up to 168 days), Identification and long term follow up of responders

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Men and non-pregnant women 18-65 years of age

• Diagnosed with T2D for at least 3 years and less than or equal to 10 years

• HbA1C of 7.5 - 10% (59-86 mmol/mol)

• BMI ≥ 24 and ≤ 40 kg/m2

• On a minimum of 1 stable oral anti-diabetic medications with no changes in medication in the previous 3 months prior to study entry Note: For subjects on sulfonylurea (SU) glucose-lowering drugs for diabetes, the only SUs permitted in the study will be glipizide or glimepiride, and their doses below half maximum labeled dosing will not be an exclusion for study entry. Subjects unwilling to reduce the dose of SU at the run-in period will be excluded.

• Agrees to use an additional glucose-lowering treatment (e.g., liraglutide, other OAD with the exception of glyburide), if recommended by the study Investigator in case of persistent hyperglycemia.

• Able to comply with study requirements and understand and sign the Informed Consent Form

Locations
Other Locations
Chile
Clinica Colonial
RECRUITING
Santiago
Contact Information
Primary
Krithika Rupnarayan, MD
krupnarayan@aquaendoscopy.com
(925)223-6392
Backup
Bosmat Friedman
bosmat.f@promedoss.com
(925)223-6392
Time Frame
Start Date: 2023-09-02
Estimated Completion Date: 2026-06
Participants
Target number of participants: 40
Treatments
Experimental: Study arm- RF Vapor Ablation arm
This is a single arm study. All enrolled patients will be included in this arm
Related Therapeutic Areas
Sponsors
Leads: Aqua Medical, Inc.

This content was sourced from clinicaltrials.gov